drugset / Trial / NCT01892046

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

NCT01892046

Phase 1 Completed 18 enrolled Esanex Inc.
NaSingle-groupOpen-labelTreatment

Summary

Heat shock protein 90 (Hsp90) is a chemical in the body that is involve in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.

Timeline

Start
2013-11
Primary completion
2017-02
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SNX-5422 Small molecule

Indications